{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:55:11Z","timestamp":1790808911545,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Peripheral intravenous 5-fluorouracil (5-FU) administration often causes phlebitis and necessitates catheter replacement, imposing burdens on both patients and healthcare providers. Insertion of a midline catheter (MLC) into the upper arm with tip positioned in the axillary vein may reduce the incidence of phlebitis. This study evaluated the safety and effectiveness of MLC use for continuous 5-FU infusion in cancer patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective study included patients with cancer requiring at least 4 days of continuous 5-FU infusion. The primary endpoint was the incidence of phlebitis. Secondary endpoints were the success rate of MLC insertion, complications, and patient-reported outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 61 patients enrolled, 59 were included in the analysis. The median age was 68 years, and primary cancer types were esophageal (51%) and head and neck (46%). The median MLC indwelling duration was 5.5 days (2-28 days). No phlebitis was observed (0%, 95% CI: 0\u20136.2), achieving the primary endpoint. The insertion success rate was 98.3%, with complications in 6.8%. Over 90% of patients and 80% of healthcare providers reported high satisfaction levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>MLC insertion is a safe and effective approach for continuous 5-FU infusion, eliminating phlebitis, potentially improving patients\u2019 quality of life, and reducing healthcare providers\u2019 workloads. (ClinicalTrials.gov Identifier: jRCTs042230058).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf108","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:05Z","timestamp":1748345825000},"source":"Crossref","is-referenced-by-count":1,"title":["Midline catheter use for cancer patients receiving 5-FU chemotherapy: prospective study of safety and outcomes"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1913-7923","authenticated-orcid":false,"given":"Tomoki","family":"Sakakida","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Fukahori","sequence":"additional","affiliation":[{"name":"Department of Nursing, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8170-3054","authenticated-orcid":false,"given":"Taro","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3305-4013","authenticated-orcid":false,"given":"Yasunobu","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehiro","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-0077","authenticated-orcid":false,"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1596","authenticated-orcid":false,"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-9771","authenticated-orcid":false,"given":"Kazunori","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5309","authenticated-orcid":false,"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-8879","authenticated-orcid":false,"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-743X","authenticated-orcid":false,"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Nursing, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Kudo","sequence":"additional","affiliation":[{"name":"Clinical Research Support Section, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1147","authenticated-orcid":false,"given":"Isao","family":"Oze","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-6682","authenticated-orcid":false,"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital , Nagoya, 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025052707365679500_CIT0001","doi-asserted-by":"publisher","first-page":"vii167","DOI":"10.1093\/annonc\/mds294","article-title":"Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines","volume":"23","author":"P\u00e9rez Fidalgo","year":"2012","journal-title":"Ann Oncol."},{"key":"2025052707365679500_CIT0002","doi-asserted-by":"publisher","first-page":"103932","DOI":"10.1016\/j.esmoop.2024.103932","article-title":"Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology","volume":"9","author":"Matsumoto","year":"2024","journal-title":"ESMO Open"},{"key":"2025052707365679500_CIT0003","doi-asserted-by":"publisher","DOI":"10.1177\/11297298241300792","article-title":"International experts consensus on optimal central vascular access device selection and management for patients with cancer","volume":"11297298241300792","author":"Jahanzeb","year":"2024","journal-title":"J Vasc Access."},{"key":"2025052707365679500_CIT0004","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.21873\/invivo.12361","article-title":"Regimen of 5-fluorouracil and cisplatin increases the incidence of extravasation in patients undergoing chemotherapy","volume":"35","author":"Tagashira","year":"2021","journal-title":"In Vivo"},{"key":"2025052707365679500_CIT0005","doi-asserted-by":"publisher","first-page":"467","DOI":"10.4103\/ijc.IJC_281_19","article-title":"5-Fluorouracil induced extravasation injury","volume":"57","author":"Reddy","year":"2020","journal-title":"Indian J Cancer."},{"key":"2025052707365679500_CIT0006","doi-asserted-by":"publisher","first-page":"e13110","DOI":"10.1111\/ijn.13110","article-title":"Safety and efficacy of midline catheters versus peripheral intravenous catheters: a pilot randomized controlled trial","volume":"29","author":"Marsh","year":"2023","journal-title":"Int J Nurs Pract."},{"key":"2025052707365679500_CIT0007","first-page":"S1","article-title":"Infusion Nurses Society. Infusion nursing standards of practice","volume":"29","year":"2006","journal-title":"J Infus Nurs."},{"key":"2025052707365679500_CIT0008","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/s0002-9343(03)00391-7","article-title":"Effective prevention of 5-fluorouracil-induced superficial phlebitis by ketoprofen lysine salt gel","volume":"115","author":"Berardi","year":"2003","journal-title":"Am J Med."},{"key":"2025052707365679500_CIT0009","doi-asserted-by":"publisher","first-page":"x156","DOI":"10.1093\/annonc\/mdx676.003","article-title":"Effects of steroid ointment application on chemotherapy-induced phlebitis: a randomized, double-blind, placebo-controlled clinical trial","volume":"28","author":"Hamabe","year":"2017","journal-title":"Ann Oncol."},{"key":"2025052707365679500_CIT0010","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/oxfordjournals.annonc.a057727","article-title":"Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck","volume":"1","author":"Planting","year":"1990","journal-title":"Ann Oncol."},{"key":"2025052707365679500_CIT0011","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/NAN.0000000000000100","article-title":"Accepted but unacceptable: peripheral IV catheter failure","volume":"38","author":"Helm","year":"2015","journal-title":"J Infus Nurs."},{"key":"2025052707365679500_CIT0012","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2131\/jts.24.113","article-title":"Experimental infusion phlebitis: tolerance pH of peripheral vein","volume":"24","author":"Kuwahara","year":"1999","journal-title":"J Toxicol Sci."},{"key":"2025052707365679500_CIT0013","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00000446-200302000-00027","article-title":"Phlebitis: a painful complication of peripheral IV catheterization that may be prevented","volume":"103","author":"Macklin","year":"2003","journal-title":"Am J Nurs."},{"key":"2025052707365679500_CIT0014","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.7326\/M15-0744","article-title":"The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND\/UCLA Appropriateness Method","volume":"163","author":"Chopra","year":"2015","journal-title":"Ann Intern Med."},{"key":"2025052707365679500_CIT0015","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamainternmed.2021.6844","article-title":"Safety and outcomes of midline catheters vs peripherally inserted central catheters for patients with short-term indications: a multicenter study","volume":"182","author":"Swaminathan","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025052707365679500_CIT0016","first-page":"2546","article-title":"Perioperative application of midline catheter and PICC in Patients with gastrointestinal tumors","volume":"24","author":"Tao","year":"2019","journal-title":"J BUON."},{"key":"2025052707365679500_CIT0017","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ppul.1950120407","article-title":"New peripherally inserted midline catheter: a better alternative for intravenous antibiotic therapy in patients with cystic fibrosis","volume":"12","author":"Harwood","year":"1992","journal-title":"Pediatr Pulmonol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf108\/63370874\/oyaf108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf108\/63370874\/oyaf108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:06Z","timestamp":1748345826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf108\/8151394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf108","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf108"}}